Applied Clinical Trials has been honored by American Business Media as a finalist in the 57th Annual Jesse H. Neal National Business Journalism Awards competition for editorial excellence. Applied Clinical Trials is one of 123 finalists selected by a distinguished board of judges for its Clinical Trial Insights column, written by Kenneth Getz, MBA, Senior Research Fellow at Tufts CSDD and Chairman of CISCRP.
The judging panel, chaired by Abe Peck of Northwestern University’s Medill School of Journalism, selected the finalists from an original pool of 660 entries. The winners will be announced on March 10 during ABM’s annual Neal Awards ceremony at the Mandarin Oriental in New York City.
Paying tribute to the Neal Award finalists, American Business Media President & CEO Clark Pettit said, “We at ABM are so proud to honor these journalists and editors. Their expertise, ability to push progress across existing and new channels, and successful track records of informing the industry on important issues place them at the forefront of their fields.”
Established in 1955, the Jesse H. Neal National Business Journalism Awards recognize and reward editorial excellence in business media. The awards are named after American Business Media’s first managing director who remained active in promoting the industry throughout his life. The Neal Awards are presented annually to those editors who have submitted entries exhibiting journalistic enterprise, service to the field and editorial craftsmanship.
Entries are divided into three classifications according to the publication’s advertising and circulation revenue, with 12 editorial categories within each size classification and seven categories that do not require revenue figures. Material must have been published between December 1, 2009, and November 30, 2010.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.